Therefore, humanized IFNAR mice offer a valuable tool for the evaluation of emerging IFN-based therapies, including treatments for viral hepatitis, respiratory illnesses (e.g. COVID-19), HCC and other tumours. This evidence concerns the gene IFNA1 and COVID-19.